Literature DB >> 21570356

The HVTN 503/Phambili study: efficacy is always the issue.

Zaneeta Dhesi1, Justin Stebbing.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21570356     DOI： 10.1016/S1473-3099(11)70103-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  2 in total

1.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Authors:  Glenda E Gray; Zoe Moodie; Barbara Metch; Peter B Gilbert; Linda-Gail Bekker; Gavin Churchyard; Maphoshane Nchabeleng; Koleka Mlisana; Fatima Laher; Surita Roux; Kathryn Mngadi; Craig Innes; Matsontso Mathebula; Mary Allen; M Julie McElrath; Michael Robertson; James Kublin; Lawrence Corey
Journal:  Lancet Infect Dis       Date:  2014-02-20       Impact factor: 25.071

2.  New prospects for a preventive HIV-1 vaccine.

Authors:  Jeffrey Brown; Jean-Louis Excler; Jerome H Kim
Journal:  J Virus Erad       Date:  2015-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.